ENDOCRINOLOGY

Control of Weight: How Do We Get Fat?

Aug 6, 2016 by in ENDOCRINOLOGY Comments Off on Control of Weight: How Do We Get Fat?

Related posts: The Classification and Diagnosis of Diabetes New Technologies for Insulin Administration and Glucose Monitoring The Role of Community and Specialist Services Transplantation The Role of the Multidisciplinary Team…

read more

Type 1 Diabetes

Aug 6, 2016 by in ENDOCRINOLOGY Comments Off on Type 1 Diabetes

Related posts: Control of Weight: How Do We Get Fat? New Technologies for Insulin Administration and Glucose Monitoring The Role of Community and Specialist Services Transplantation The Role of the…

read more

The Classification and Diagnosis of Diabetes

Aug 6, 2016 by in ENDOCRINOLOGY Comments Off on The Classification and Diagnosis of Diabetes

Related posts: Control of Weight: How Do We Get Fat? New Technologies for Insulin Administration and Glucose Monitoring The Role of Community and Specialist Services Transplantation The Role of the…

read more

The Incretin Mimetics

Aug 6, 2016 by in ENDOCRINOLOGY Comments Off on The Incretin Mimetics

Exenatide clinical efficacy The Phase 3 clinical efficacy studies that have been conducted with exenatide are listed in Table 4.1. Three 30-week, placebo-controlled studies evaluated exenatide (5 µj.g or 10…

read more

Dipeptidyl Peptidase-4 Inhibitors

Aug 6, 2016 by in ENDOCRINOLOGY Comments Off on Dipeptidyl Peptidase-4 Inhibitors

In a 52-week active-comparator study, patients not achieving adequate glycaemic control on a metformin dose of at least 1500 mg/day were randomized to sitagliptin 100 mg once daily or glipizide,…

read more

Epidemiology and Pathogenesis of Type 2 Diabetes

Aug 6, 2016 by in ENDOCRINOLOGY Comments Off on Epidemiology and Pathogenesis of Type 2 Diabetes

Related posts: The Incretin System Overview of Current Diabetes Management Bariatric Surgery for the Treatment of Type 2 Diabetes Sodium-glucose Cotransporter-2 Inhibitors Dipeptidyl Peptidase-4 Inhibitors The Incretin Mimetics

read more

Sodium-glucose Cotransporter-2 Inhibitors

Aug 6, 2016 by in ENDOCRINOLOGY Comments Off on Sodium-glucose Cotransporter-2 Inhibitors

Figure 6.2 Adjusted mean (95% CI) percent change from baseline in body weight after 12 weeks of dapagliflozin treatment. Reproduced from List et al. (2009) with permission from the American…

read more

Pipeline Diabetes Therapies

Aug 6, 2016 by in ENDOCRINOLOGY Comments Off on Pipeline Diabetes Therapies

Related posts: The Incretin System Overview of Current Diabetes Management Sodium-glucose Cotransporter-2 Inhibitors Epidemiology and Pathogenesis of Type 2 Diabetes Dipeptidyl Peptidase-4 Inhibitors The Incretin Mimetics

read more

The Incretin System

Aug 6, 2016 by in ENDOCRINOLOGY Comments Off on The Incretin System

Related posts: Overview of Current Diabetes Management Organization of Diabetes Care Sodium-glucose Cotransporter-2 Inhibitors Epidemiology and Pathogenesis of Type 2 Diabetes Dipeptidyl Peptidase-4 Inhibitors The Incretin Mimetics

read more
Get Clinical Tree app for offline access